Anne Gurnett

TL;DR: A novel fungal metabolite, apicidin, that exhibits potent, broad spectrum antiprotozoal activity in vitro against Apicomplexan parasites has been identified and is also orally and parenterally active in vivo against Plasmodium berghei malaria in mice.

TL;DR: The variable domain of the trypanosome variant surface glycoprotein (VSG) ILTat 1.24 has been shown by X-ray crystallography to resemble closely the structures of VSG MIT at 1.2, despite their low sequence similarity.

TL;DR: A parasite signature sequence of nearly 300 amino acids that is not found in mammalian or DrosophilaPKG and which contains an additional, third cGMP-binding site is identified, which represents the first example of a protozoal PKG.

TL;DR: Compounds 10a and 21 are the most potent inhibitors of Eimeria tenella cGMP-dependent protein kinase activity and are efficacious in the in vivo antiparasitic assay when administered to chickens, but both compounds are positive in the Ames microbial mutagenesis assay which precludes them from further development as antiprotozoal agents.

TL;DR: The conversion of apicidin, a nonselective nanomolar inhibitor of HDACs, into a series of picomolar indole-modified and parasite-selective tryptophan-replacement analogues is described within this structure-activity study.